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Summary 
Compound IG20 is a newly synthesised sulphated glycolipid that promotes 
neuritic outgrowth and myelinisation, at the time it causes the inhibition of glial 
proliferation and facilitates exocytosis in chromaffin cells. Here we have shown that 
IG20 at 0.3-10 M afforded neuroprotection in rat hippocampal slices stressed with 
veratridine, glutamate or with oxygen plus glucose deprivation followed by 
reoxygenation (OGD/reox). Excess production of reactive oxygen species (ROS) 
elicited by glutamate or ODG/reox was prevented by IG20 that also restored the 
depressed tissue levels of GSH and ATP in hippocampal slices subjected to OGD/reox. 
Furthermore, the augmented iNOS expression produced upon OGD/reox exposure was 
also counteracted by IG20. Additionally, the IG20 elicited neuroprotection was 
prevented by the presence of inhibitors of the signalling pathways Jak2/STAT3, 
MEK/ERK1/2, and PI3K/Akt, consistent with the ability of the compound to increase 
the phosphorylation of Jak2, ERK1/2, and Akt. Thus, the activation of phase II response 
and the Nrf2/ARE pathway could explain the antioxidant and anti-inflammatory effects 
and the ensuing neuroprotective actions of IG20.  
 
 
Keywords: Sulfoglycolipid IG20, neurotoxicity, neuroprotection, oxidative stress, 
neuronal excitability, hippocampal slices, hippocampal neurons 
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1.- Introduction 
Sulfoglycolipid IG20 was designed and synthesised at our laboratory in the 
context of a programme to obtain new compounds aimed at promoting neuritogenesis 
and myelinisation, with a special focus to inhibit glial proliferation. This last property 
mainly focused the treatment of cerebral gliomas (Doncel-Perez et al., 2013; Fernandez-
Mayoralas et al., 2003; Garcia-Alvarez et al., 2007). The synthetic strategy was inspired 
in the fact that in mammalian brain there are natural inhibitors of astroblasts and 
astrocytes division (Nieto-Sampedro, 1988; Nieto-Sampedro and Broderick, 1989); one 
such inhibitor is neurostatin, first found in the rat brain (Valle-Argos et al., 2010). 
Although neurostatin happened to be a very potent blocker of glial proliferation, its 
molecular complexity makes difficult its purification from brain tissue or its laboratory 
synthesis. Thus, the simple compound IG20 was synthesised and although with lesser 
potency, it shared with neurostatin its ability to inhibit gliomas growth (Garcia-Alvarez 
et al., 2007). Recently, IG20 was shown to inhibit astrocyte and microglia proliferation, 
the main cellular components of the glial scar, and promote axonal outgrowth and 
myelin production in vitro (Garcia-Alvarez et al., 2015). This compound has a structure 
very similar to sulfatides, a class of sulfated galactosylceramides that are synthesised 
mainly in brain oligodendrocytes and belong to the great family of sphingosine derived 
sphingolipids  (Honke, 2013) (Fig.1). 
From a drug therapy point of view, compounds like IG20 could have various 
potential clinical applications. For instance, sulfatides are known to play a relevant role 
in myelin stabilisation and function (Coetzee et al., 1996). In fact, KO mice for sulfatide 
synthesising enzyme develop thinner myelin sheets and progressive paralysis (Honke, 
2013). Also, a recent study shows changes in sulfatide brain levels at early stages of 
Alzheimer´s disease (AD) (Cheng et al., 2013). Thus, the ability of IG20 to inhibit 
astrocyte and microglia proliferation indicates its potential therapeutic application to 
mitigate the neuroinflammatory component in the pathogenesis of AD and Parkinson´s 
disease (PD). Additionally, in promoting myelinisation, IG20-type compounds could 
find a clinical application in multiple sclerosis. Finally, IG20 could also be potentially 
useful in brain repair after a traumatic brain or spinal cord damage; in these conditions, 
the recruitment of inflammatory cells and astrocytes contribute to the formation of a 
glial scare that impede axonal growth and regeneration (Yiu and He, 2006) and IG20-
like compounds could prevent the formation of the glial scare.  
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We have recently found that IG20 facilitates the exocytotic release of 
transmitter, apparently through the regulation of a voltage-dependent sodium channel 
current in bovine chromaffin cells (Crespo-Castrillo et al., 2015). This property may 
additionally contribute to the ability of IG20 to promote synaptic plasticity. 
Additionally, the inhibition of glial proliferation and augmentation of neuritogenesis 
could translate into a neuroprotective effect of IG20. We have explored here this 
hypothesis in acutely isolated rat hippocampal slices stressed with various neurotoxic 
stimuli. We have found that IG20 exhibited a clear neuroprotective effect that was 
associated to its ability to activate the phase II antioxidant response that includes among 
others, haemoxygenase-1 (HO-1) and the catalytic subunit of glutamate-cysteine ligase 
(GCLcat), the rate-limiting enzyme for glutathione (GSH) (Egea et al., 2015; Zhang et 
al., 2013). 
 
2.- Material and methods 
2.1.- Synthesis of compound IG20 
IG20 was synthesized using a new procedure which involves a regioselective sulfation 
(Garcia-Alvarez et al., 2015). Briefly, oleyl N-acetylglucosaminide in anhydrous 
pyridine was treated with SO3-pyridine complex (1.2 equiv) at 0 °C for 1.5 h and at 
room temperature for 2 h. The solvent was removed and the residue was dissolved in 
2:1 MeOH-H2O, neutralized with a 0.5 M KOH solution and concentrated. The residue 
was purified by silica gel column chromatography (CH2Cl2/MeOH, 4:1 to 2:1) to give 
IG20 as a white solid (81%). 
 
2.2.- Preparation of hippocampal slices 
All experiments were carried out in accordance with the code of ethics and 
guidelines established by European Community Directive (2010/63/EU) and Spanish 
legislation 1201/2005. All animals used in this study were provided by the local 
university’s facilities where they were housed (EX 021-U). All efforts were made to 
minimise the number of animals and their suffering. 
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Experiments were performed in hippocampal slices prepared from brains of 
adult male Sprague-Dawley rats (Rattus norvegicus; 250-300 g weight). Rats were 
killed by decapitation under anaesthesia with sodium pentobarbital (60 mg/Kg i.p.). The 
brain was rapidly removed from the skull and placed into oxygenated ice-cold Krebs-
bicarbonate dissection buffer containing (in mM): NaCl 120, KCl 2, NaHCO3 26, 
KH2PO4 1.18, CaCl2 0.5, glucose 11, sucrose 200 and MgSO4 10. Slices (300 µm thick) 
were prepared using a Mcllwain tissue chopper and separated in ice-cold dissection 
buffer. Then they were immediately transferred to a vial containing sucrose-free buffer 
of the following composition (in mM): NaCl 120, KCl 2, NaHCO3 26, KH2PO4 1.18, 
CaCl2 2, glucose 11 and MgSO4 1.19; it was bubbled with 95% O2 and 5% CO2 for 45 
min at 34°C to recover from slicing trauma. After the stabilisation period, slices were 
bubbled during 30 min at 37°C in a control buffer containing (in mM): NaCl 120, KCl 
2, NaHCO3 26, KH2PO4 1.18, CaCl2 2, glucose 11 and MgSO4 1.19. 
 
 2.3.- Cell Cultures 
For the isolation and culture of hippocampal neurons, pregnant Sprague-Dawley 
rats were decapitated under anaesthesia with sodium pentobarbital (60 mg/Kg i.p.) and 
18-day embryos were removed immediately by caesarean section. Hippocampi were 
dissected rapidly under a stereomicroscope and sterile conditions in ice-cold phosphate 
buffer solution (PBS) of the following composition (in mM): NaCl, 137; KCl, 2.7; 
NaH2PO4, 11.6; and KH2PO4 1.47 (pH 7.4, adjusted with NaOH). The tissue was 
digested with 0.5 mg/mL papain (Sigma-Aldrich. Madrid, Spain). The enzyme was 
dissolved in a Ca
2+
- and Mg
2+
-free PBS solution containing 1 mg/mL BSA and 10 mM 
glucose at 37°C for 20 min. The papain solution was replaced with 5 mL of Neurobasal 
medium (Gibco-Invitrogen; Barcelona, Spain) supplemented with 1% foetal bovine 
serum (Sigma-Aldrich, Madrid, Spain). The digested tissue was then gently triturated by 
suction using a glass pipette flamed on the tip to avoid cellular damage. Cell suspension 
was centrifuged for 2 min at 120xg. The supernatant was removed and the cells were 
resuspended in 5 mL Neurobasal medium and centrifuged again for 5 min to remove all 
the enzyme. Finally, the supernatant was replaced with fresh medium, the cells were 
resuspended and plated at a density of 120.000 cells/mL in poly-D-lysine (Sigma-
Aldrich) 24-well plates (Nunc, Thermo Fisher Scientific, Madrid, Spain) in Neurobasal 
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medium supplemented with 1% foetal bovine serum and 2% B27 supplement (Gibco), 
to facilitate hippocampal neuron survival in vitro. Under these conditions the standard 
cell survival was 4 weeks and the experiments were performed on neurons of 8-15 days 
in culture. 
In a few experiments on neurotoxicity, cortical neurons were prepared from rat 
embryo that were prepared essentially following the procedure used to prepare 
hippocampal neurons. Similar neurotoxicity experiments were performed in primary 
cultures of bovine adrenal chromaffin cells (BCCs) that were prepared as described by 
Moro et al. (1990) as well as in the tumoral cell line from human neuroblastoma SH-
SY5Y that were prepared as previously described (Arias et al., 2005).  
  (Moro et al., 1990)   
2.4.- Evaluation of cell viability  
Cell viability was measured by quantitative colorimetric assay by using the 
MTT-based method (3-[4,5-dimethylthiazo1-2-y1]-2,5-diphenyltetrazolium bromide). 
MTT (Sigma-Aldrich) was added into the wells (0.5 mg/mL) and incubated at 37°C for 
15 min. The tetrazolium ring of MTT can be cleaved by active dehydrogenases to 
produce a precipitated formazan that was solubilised with dimethyl sulfoxide (DMSO); 
cellular viability was quantified in a colorimetric reader at 560 nm (FLUOstar Optima, 
BMG, Germany). Data were expressed as percentage of MTT reduction, taking the 
maximum control tissue capability in each individual experiment as 100%.  
 
2.5.- Neuronal viability experiments in rat hippocampal slices stressed with 
veratridine or glutamate 
Experiments were performed at 37°C. Protocols are shown on top of the 
corresponding figures. Control and neurotoxicity groups were included in all 
experiments. Hippocampal slices were collected at the end of the experiment and 
incubated with MTT to determine cell viability. In experiments with veratridine, a 
positive control with tetrodotoxin (TTX, Tocris, Biogen Científica, Spain) was 
included. 
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2.6.- Cell viability experiments in rat hippocampal slices subjected to oxygen and 
glucose deprivation (OGD) plus reoxygenation 
Following the period of stabilisation, slices were incubated for 15 min in an 
OGD buffer of the following composition (in mM): CaCl2 2, NaCl 120, KCl 2, MgSO4 
1,19, KH2PO4 1,18; glucose was replaced by 11 mM 2-deoxy-glucose, equilibrated with 
a 95% N2 and 5% CO2 gas mixture. After this OGD period, slices were reoxygenated 
during 2 h in control buffer, bubbled with 95% O2 and 5% CO2 at 37°C, and finally cell 
viability was measured by MTT assay.  
 
2.7.- Calcium measurements in populations of hippocampal neurons  
Calcium measurements were performed with the selective calcium sensitive 
fluorescent dye Fluo-4 AM as previously described (Tenti et al., 2014). Briefly, Cells 
were plated into black 96-well plates at high density (45.000 cells/well). After removing 
the medium, cells were incubated with the Ca
2+
 fluorescent probe Fluo-4 (Gibco-
Invitrogen) at 5 µM in Neurobasal Medium (Gibco-Invitrogen). After 45 min, cells 
were washed with Krebs-HEPES buffer of the following composition (in mM): NaCl 
144, KCl 5.9, MgCl2 1.2, glucose 11, HEPES 10, pH 7.4). Compound was dissolved in 
the same buffer and incubated for 10 min. Fluorescence measurements were carried out 
on the fluorescence plate reader FLUOstar Optima (BMG Labtech GmbH; Ortemberg; 
Germany) using an excitation wavelength of 488 nm and recording the emission at 522 
nm. Glutamate injection causes an increase in [Ca
2+
]c, and this leads to an increase in the 
emission fluorescence intensity of the probe. 
 
2.8.- Measurement of ROS production 
To measure the cellular production of reactive oxygen species (ROS), the 
molecular probe 2´,7´-dicholorofluorescein diacetate (H2DCFDA) (Gibco-Invitrogen) 
was used. Hippocampal slices were loaded with 20 µM H2DCFDA for 45 min at 37°C. 
H2DCFDA diffuses through the cell membrane and is hydrolysed by intracellular 
esterases to the non-fluorescent form. This form reacts with intracellular ROS (including 
hydrogen peroxide, hydroxyl radicals and peroxynitrite) to form ROS 
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dichlorofluorescein, a green fluorescent dye. Fluorescence was measured in a 
fluorescence inverted NIKON eclipse T2000-U microscope (Nikon Europe B.V., 
Amsterdam, Netherlands). Wavelengths of excitation and emission for H2DCFDA were 
450 and 490 nm, respectively. 
 
2.9.- Measurement of ATP in hippocampal slices 
Intracellular ATP content was measured with a luminescence ATP Kinase-Glo® 
detection assay according to the manufacturer’s instructions (Promega, Madrid, Spain). 
At the end of the experiment, hippocampal slices were disgregated by sonication (3-10 
s, power 2) in 100 l of potassium phosphate buffer (0.1 M, pH = 7.4), centrifuged and 
the supernatant was collected; 40 μl of the supernatant were placed in a white multiwell 
plate and 40 l of the substrate was added into each well. Luminescence in each sample 
was measured with an Orion II microplate luminometer (Berthold, Germany). ATP 
content was normalized to the ATP content of control slices without any treatment.  
 
 
2.10.- Intracellular GSH measurement  
Hippocampal slices were treated as described for acute OGD/reox ischemia model as 
previously described (Egea et al., 2015). Briefly, to measure reduced glutathione (GSH) 
we selected monochlorobimane, a fluorescent dye that exhibits low fluorescent intensity 
when is unreacted; once it reacts with GSH it forms a highly fluorescent adduct 
(Fernandez-Checa and Kaplowitz, 1990) mediated by glutathione S-transferase 
(Kamencic et al., 2000). After the OGD/reox treatment, hippocampal slices were 
suspended in 50 L potassium phosphate buffer and disgregated by sonication (3-10 s, 
power 2) in ice. The reaction started by the addition of monochlorobimane (100 M) 
and glutathione S-transferase (0.5 U/mL) to a final volume of 100 L. Fluorescence was 
measured in a FLUOstar optima microplate fluorescence reader (BMG technologies, 
Germany) at excitation and emission wavelengths of 410 and 485 nm respectively over 
1 h at room temperature. Results were normalized to the basal conditions taken as 100 
% GSH content. 
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2.11.- Western blot analysis 
Slices of each experimental group were lysed in 100 L ice-cold lysis buffer 
containing: 1% Nonidet P-40, 10% glycerol, 137 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 
g/mL leupeptin, 1 mM PMSF, 20 mM NaF, 1 mM sodium pyrophosphate and 1 mM 
Na3VO4. Proteins (30 g) from these lysates were resolved by SDS-PAGE and 
transferred to Immobilon-P membranes (Millipore Millipore Corp.). Membranes were 
incubated with anti-HO-1 (1:1000), anti-GCLcat (1:1000) and anti--actin (1:50000) 
antibodies. Appropriate peroxidase-conjugated secondary antibodies (1:10000) were 
used to detect proteins by enhanced chemoluminescence. Protein bands were scanned 
and density was analysed using the Scion Image analysis software (Scion Corporation, 
NIH, Bethesda, MD, USA). Expression of HO-1 is presented as densitometric 
quantification using -actin for normalisation. 
 
2.12.- Recording of the spontaneous electrical activity of hippocampal neurons 
Spontaneous postsynaptic currents (sPSCs), were recorded under voltage-clamp 
mode of the patch-clamp technique; the resting membrane potential (Vm) and the 
spontaneous action potentials (sAPs) were recorded under the current-clamp mode. The 
perforated-patch configuration of the patch-clamp technique was used in all cases. 
Recordings were made with fire-polished electrodes (resistance 3-5 MΩ) 
mounted on the head stage of an EPC-9 patch-clamp amplifier (HEKA Elektronik, 
Lambrecht, Germany), allowing cancellation of capacitative transients and 
compensation for series resistance. Data were acquired at sampling frequencies ranging 
between 5 and 10 kHz and filtered at 1-2 kHz. 
The perforated patch was obtained using pipettes containing 50-100 µg/mL 
amphotericin B (Sigma-Aldrich, Madrid, Spain) as permeabilising agent and a pipette-
filling solution containing (in mM): NaCl, 10; K-glutamate, 120; Mg-ATP, 5; Na-GTP, 
0.3; HEPES, 20; and EGTA, 14 (pH 7.2 with KOH). Amphotericin B was dissolved in 
DMSO and stored at -20°C in stock aliquots of 50 mg/mL. A fresh pipette solution was 
prepared every 2 h. To facilitate its sealing, the pipette was first dipped in a beaker 
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containing the internal solution and then back-filled with the same solution containing 
amphotericin B. 
Recordings with leak currents >100 pA or series resistance >30 MΩ were 
discarded. Coverslips containing the cells were placed in an experimental chamber 
mounted on the stage of a Nikon T2000-U inverted microscope. The cell being recorded 
was locally, rapidly and continuously superfused with a Tyrode’s solution containing 
(in mM): CaCl2, 2; NaCl, 137; MgCl2, 1; glucose, 10; KCl, 5; and HEPES-NaOH, 10 
(pH 7.4). External solutions were rapidly exchanged using electronically driven 
miniature solenoid valves coupled to a multibarrel concentration-device, the common 
outlet of which was placed within 100 µm of the cell to be patched. 
Data acquisition was performed using PULSE software (HEKA Elektronik). 
Data analysis was performed with the MiniAnalysis software (Synaptosoft, Leonia, NJ, 
USA). All experiments were performed at room temperature (22-24 °C).  
 
2.13.- Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM). Comparisons 
between experimental and control groups were performed by one-way ANOVA 
followed by Newman-keuls post-hoc test, as required. The Student’s t test was also used 
for paired data comparisons (namely, control versus a given treatment) within the same 
experiment. Differences were considered to be statistically significant when p ≤ 0.05. 
All statistical procedures were carried out using GraphPad Prism 5.0. 
 
2.14.- Solutions and compounds 
Both IG20 and glutamate (Sigma-Aldrich) are soluble in water, and the stock 
solutions were at the concentration of 10 mM and 1 M, respectively. Veratridine 
(Sigma-Aldrich) was dissolved in DMSO (Sigma-Aldrich) and stored at 10 mM. All 
solutions were stored in aliquots at -20°C. The final concentration of DMSO used 
(always <0.1%) did not cause cell toxicity.  
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3.- RESULTS 
Most of the experiments here described were done in acutely isolated rat 
hippocampal slices and in primary cultures of rat hippocampal neurons prepared from 
the brains of E18 rat embryos. The use of slices implied a higher level of physiological 
and pathophysiological approaches to the neurotoxicity and neuroprotection studies. On 
the other hand, the patch-clamp studies requiring the recording of sPSCs at the single-
cell level were done in cultures of rat embryo hippocampal neurons. Nevertheless, 
primary cultures of rat cortical neurons and bovine adrenal chromaffin cells, as well as 
some cultures of the human neuroblastoma cell line SH-SY5Y were used in some 
experiments aimed at testing the potential neurotoxic effects of compound IG20 
(Supporting information). 
 
3.1.- Effects of IG20 on neurotoxicity elicited by veratridine, glutamate and acute 
ischemia model in hippocampal slices 
Veratridine has been used as a neurotoxic stressor to elicit a state of vulnerability 
and cell death associated to Na
+
 and Ca
2+
 overload in rat embryo cortical neurons 
(Pauwels et al., 1990), in bovine chromaffin cells (Maroto et al., 1994; Nicolau et al., 
2009), and in rat hippocampal slices (Nicolau et al., 2010).Thus, we performed an initial 
set of experiments to inquire whether compound IG20 exerted neuroprotection against 
the neurotoxic effects of veratridine in acutely isolated hippocampal slices. 
We first performed a dose-dependent toxicity curve in our hippocampal slices 
model to test whether IG20 itself exerted neurotoxic effects on various cell cultures and 
in hippocampal slices. IG20 only had a clear toxic effects in SH-SY5Y cells at 300 M. 
In hippocampal slices, BBCs or hippocampal neuronal cultures IG20 at 0.2-100 M did 
not exhibit neurotoxic effects (see Fig. SI1 in Supporting information).  
After an initial 30 min resting period, the slices were incubated with increasing 
concentrations of veratridine for 1 h; then, cell viability with the mitochondrial probe 
MTT was estimated (Fig. SI2A). We choose 10 µM veratridine that approximately 
caused 40% cell death, to perform the following experiments with veratridine and IG20. 
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In these experiments we used the protocol shown on top of Fig. 2A. Slices were 
exposed to increasing IG20 concentrations during the initial 30 min resting period; then 
they were exposed to continued IG20 plus 10 µM veratridine during an additional 60 
min period that was followed by the MTT assay. In 6 triplicate experiments, veratridine 
decreased cell viability to 63.4 ± 3 % of the basal value (p < 0.001); cell viability 
increased to 77.3 ± 4 %  in the presence of veratridine plus 0.3 µM IG20 (p < 0.01); the 
compound did not increase further this parameter at 1 and 10 µM. As expected, the 
blocker of voltage-dependent Na
+
 channels TTX at 1 µM, fully antagonised the 
veratridine elicited cell damage (Fig. 2A).  Under these conditions IG20 afforded 40 ± 6 
% (p< 0.05) protection at 0.3 μM and 48.6 ± 8% (p < 0.01) protection at 10 μM (Fig. 
2A). 
The concept of neurotoxicity implies an excess glutamate release and/or the 
deficient removal of synaptic glutamate, which results in overactivation of NMDA and 
AMPA receptors, the cell overload with Na
+ 
and Ca
2+
,
 
and cell death (Lau and 
Tymianski, 2010; Zundorf and Reiser, 2011). Hence, the neuroprotective effects of 
IG20 on veratridine elicited Na
+
 and Ca
2+
 overload and cell damage, prompted the 
experiments with glutamate. After protocol optimization (Fig. SI3B), we selected the 
toxicity induced by 4 mM glutamate after 2 h exposure and 2 h recovery (30.5 ± 0.8 % 
decreased viability) to test the potential neuroprotective effect of our compound. 
IG20 at increasing concentrations was present only during the 2 h recovery 
period (see protocol on top of Fig. 2B). We found an improved significant cell viability 
at the IG20 concentrations of 0.3 (47.6 ± 9 %, p< 0.01) and 3 µM (51.6±13%, p< 0.01), 
but not at the concentrations of 1 and 10 µM that although they exhibited some 
tendency for improvement, these values did not reach the level of statistical significance 
(Fig. 2B).  
It was of interest to inquire the possibility that IG20 could afford protection on 
in vitro models of transient cerebral ischemia. This was studied in hippocampal slices 
subjected to a transient period of OGD followed by another period of reoxygenation. In 
so doing, the excess ROS production will cause neuronal damage (Egea et al., 2007b). 
The protocol on top of Fig. 2C indicates the experimental steps that were followed; the 
increasing concentrations of IG20 were present at all stages of this protocol. We found a 
protective effect of the compound against cell tissue damage at all concentrations tested 
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(1, 3 and 10 M). Hence, OGD reduced cell viability to 62.2 ± 1.7 % (p < 0.001). Cell 
viability was significantly increased to 76.3 ± 4.8 % (p < 0.01) at 1 M IG20 and to 
82.3 ± 4.2 % at 3 M (p < 0.001) were the compound showed the best neuroprotective 
effect against toxicity elicited by OGD/reox. This effect was slightly reduced at 10 M 
were compound IG20 increased cell viability to 75.2 ± 4.3 % (p < 0.01). 
 
3.2.- IG20 reduces ROS production induced by glutamate and OGD/reox and 
prevents tissue depletion of GSH and ATP 
In order to evaluate the mechanism of action involved in the neuroprotective 
effects of IG20 we first tested the possibility that the compound mitigated Ca
2+ 
overload 
in neurons challenged with glutamate, as Ca
2+ 
is linked to the neurotoxic effects of 
glutamate (Lau and Tymianski, 2010; Zundorf and Reiser, 2011). However, IG20 was 
not able to reduce the cytosolic Ca
2+
 elevations ([Ca
2+
)c]  induced by glutamate (100 
M) at any concentration tested (0.1 to 10 M) (see supporting information, Fig. SI3).  
The protection exerted by IG20 against the neurotoxic effects of glutamate in 
hippocampal slices could be associated to the mitigation of excess ROS production. To 
test this possibility, we performed experiments with the same protocol to that followed 
in the neurotoxicity-neuroprotection experiments namely, the incubation of 
hippocampal slices for 2 h with 4 mM glutamate and in the experimental group of 
slices, an additional 2 h incubation period with 3 µM IG20. ROS production was 
monitored at the end of the experiment with the fluorescent probe H2DCFDA, an 
indicator of the tissue concentration of ROS.  
Fig. 3A shows representative micro-images on the relative fluorescence intensity 
as an index of tissue ROS production in basal conditions, in the presence of glutamate 
with 2 additional 2 h recovery period, and in tissues incubated first with glutamate for 2 
h and then with IG20 (at 3 µM) during the recovery period. Glutamate induced a 62 ± 8 
% increased of ROS production (Fig. 3C). Compound IG20 effectively reduced ROS 
production almost to basal levels (13.6 ± 0.8 % increase, p < 0.01).  
We were also interested in evaluating ROS production induced by OGD/reox in 
hippocampal slices. Oxygen deprivation induces mitochondrial depolarization leading 
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to increased ROS production; furthermore, the reoxygenation period exacerbates the 
production of free radicals augmenting the neuronal damage. Fig. 3B shows 
representative micro-images of ROS production induced by OGD/reox in hippocampal 
slices in basal conditions, slices subjected to OGD/reox and slices treated with IG20 (3 
M) following the protocol described in Fig. 2C. Quantification of ROS production 
resulted in an increased fluorescence intensity induced by OGD/reox to 77.9 %. 
Compound IG20 significantly reduced the excess ROS production by 71.4 %, compared 
with OGD/reox treated slices (p < 0.01). 
 The first defence system against free radicals production inside the cell is 
glutathione (GSH), which reacts with free radicals and pro-oxidant species to avoid 
oxidative stress damage. Hippocampal slices were subjected to OGD/reox as described 
in Fig. 2C in absence or presence of IG20 (3 M). At the end of the reoxygenation 
period, hippocampal slices were disaggregated and GSH content was measured with the 
fluorescent dye monochlorobimane. As shown in Fig. 3E, OGD/reox significantly 
reduced the levels of GSH to 77.7 ± 5.2 % (p < 0.001) compared with basal conditions. 
Interestingly, slices treated with compound IG20 maintained GSH levels (93.6 ± 4.0 %) 
compared with basal levels being able to recover 71.3 % (p < 0.01) of GSH depletion 
induced by OGD/reox insult. 
On the other hand, mitochondrial depolarization during OGD induces an acute 
drop in ATP levels (Chen et al., 2010) that has been related with cell death observed in 
ischemia. To determine the potential abrogation of ATP decreased levels by IG20, ATP 
levels were determined. As shown in Fig. 3E, compared with basal slices, OGD/reox 
induced a marked decrease of ATP levels to 34.3 ± 6.6 % (p < 0.001). Slice incubation 
with 3 M IG20 successfully maintained ATP levels at 58.0 ± 8.6 % (p < 0.05), being 
able to recover 36 % of ATP drop after OGD/reox.  
 
3.3.- IG20 induces Nrf2/ARE phase II response and reduces iNOS expression in 
hippocampal slices subjected to OGD/reox toxic insult 
Whether the antioxidant activity of IG20 was associated to the induction of HO-
1 was investigated in rat hippocampal neuronal cultures. Cells were incubated with 
increasing concentrations of IG20 during 24 h at 37°C and HO-1 protein density was 
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estimated with western blot at the end of this incubation period. A prototype western 
blot is shown in Fig. 4A. IG20 (3 µM) augmented by 7.4-fold HO-1 concentration (p < 
0.01) and 2.4-folds GCLcat concentration (Fig. 4B, p < 0.05) two of the most important 
neuroprotective and anti-oxidant enzymes regulated by the Nrf2/ARE pathway.  
We also analysed the expression of the pro-inflammatory enzyme inducible NO 
synthase (iNOS). OGD/reox induces glial activation and therefore, iNOS expression is 
highly increased. Fig. 4C shows the induction of iNOS expression upon OGD/reox 
exposure, that augmented 2-fold compared with basal conditions; compound IG20 
successfully reduced iNOS expression almost to basal levels, namely to 1.13-fold over 
basal (p < 0.05) indicating the anti-inflammatory potential of IG20.  
 
3.4.- The neuroprotective effects of IG20 partially depend on the PI3K/Akt, 
ERK1/2 and Junk pathways 
 As described above, the mechanism of action by which compound IG20 exerts 
its neuroprotective effect against OGD/reox partially depends on the phase II 
antioxidant response. However, the expression of phase II antioxidant enzymes is time 
dependent and probably, there are other mechanisms of action that complement the 
neuroprotective profile of compound IG20. To further elucidate the participation of 
other neuroprotective pathways in the mechanism of action of IG20 we performed the 
OGD/reox protocol as described in Fig. 5A in presence of IG20 or IG20 combined with 
the Jak2/STAT3 inhibitor AG490, the MEK/ERK1/2 inhibitor PD98059 and the 
PI3K/Akt antagonist LY294002, at 10 M each. Previously, we demonstrated that these 
inhibitors had no effect on cell death induced by OGD/reox (Buendia et al., 2015a; 
Buendia et al., 2015b). As shown in Fig. 5A, slices incubated with IG20 showed an 
increased cellular viability compared with those subjected only to OGD/reox insult 
(52.6 ± 2.1 % cell viability increase, p < 0.001). So, it seems that the mechanism of 
action of IG20 partially depends also on the Jak2/STAT3 pathway, on the ERK1/2 
pathway and on the PI3K/Akt pathway as all three inhibitors tested partially reverted the 
neuroprotective effect of IG20 by 49.6 % (AG490, p < 0.01), 24.4 % (PD98059, p < 
0.05) and 48.1 % (LY294002, p < 0.05), respectively. 
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 To further demonstrate the involvement of these pathways in the neuroprotective 
effect of compound IG20 we used rat primary neuronal cultures. Neurons were 
incubated with the compound at 3 M. Neurons were collected after 15 min, 30 min and 
60 min incubation with IG20 and protein phosphorylation was evaluated by western 
blot. As shown in Fig. 5B and 5C, compound IG20 significantly increased the 
phosphorylation of ERK1/2 and Akt at the incubation time of 60 min (pERK1/2) and at 
30 min incubation (Akt).  
 
3.5.- Effects of IG20 on the spontaneous postsynaptic currents and action 
potentials in cultured hippocampal neurons  
In a recent study we found that IG20 exerted a modulatory effect on Na
+ 
currents 
(INa) in bovine chromaffin cells (Crespo-Castrillo et al., 2015). Thus, it was possible that 
IG20 could also exhibit some actions on the sPSCs and on sAPs in hippocampal neuron 
cultures. 
Under the voltage-clamp configuration of the patch-clamp technique, the example 
neuron of Fig. 6A fired sPSCs that are due to stimulation by glutamate and GABA of 
glutamatergic and gabaergic receptors (Arnaiz-Cot et al., 2008). This firing pattern lasts 
for several minutes and thus, the effects of 1 and 10 µM concentrations of IG20 on such 
sPSCs could be longitudinally tested within the same neuron. Note that 1 µM caused a 
mild but visible reduction in sPSCs frequency; at 10 µM, however, a drastic reduction 
in frequency and sPSCs amplitude was produced, an effect that was quickly reversed 
upon IG20 washout. Averaged data on normalised frequency amplitude, and integrated 
area of sPSCs are graphed in Fig. 6B, C and D. At 1 µM, IG20 reduced the frequency 
by 37 ± 4 % (p < 0.05), the amplitude by 17 ± 1.8 %, and the area by 35.2 ± 3.5 % (p < 
0.01). At 10 µM, the reductions of the 3 parameters were 43.3 ± 5 % (p < 0.01) for the 
frequency, 43.8 ± 4 % (p < 0.001) for amplitude, and 61 ± 6 % (p < 0.001) for the area.  
We also tested the effect of IG20 on the frequency of sAPs recorded in 
hippocampal neurons under the current-clamp configuration of the patch-clamp 
technique. Fig. 7A shows an example record of sAPs before or during the cell exposure 
to 1 and 10 µM IG20; note the mild reduction of AP frequency at 1 µM and the more 
drastic reduction of frequency and amplitude of the APs in the presence of 10 µM IG20, 
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a drastic effect that fully reversed upon its washout. Averaged data from 5 different 
neurons indicated that at 1 µM AP frequency was reduced by 41 ± 4 % (p < 0.01) and at 
1 µM IG20 such reduction augmented to 65 ± 6 % (p < 0.001) (Fig. 7B). 
 
4.-DISCUSSION 
Central in this study was the finding that the novel synthetic sulfoglycolipid 
IG20 afforded neuroprotection in rat hippocampal slices whose neurons were made 
vulnerable with three different stressors namely, veratridine, glutamate, and OGD/reox 
(Fig. 2). We also found that by itself, IG20 did not cause cell damage in a wide range of 
concentrations and in 5 different cell models namely, rat cortical and hippocampal 
neurons, bovine chromaffin cells, rat hippocampal slices, and the cell line human 
neuroblastoma SH-SY5Y; only at the high concentrations of 30 µM in cortical neurons 
and 300 µM in SH-SY5Y cells, did IG20 cause notable damage (Fig. SI1, Supporting 
info). Of interest was the fact that IG20 augmented cell viability at 3-30 µM in SH-
SY5Y cells and at 100 µM in bovine chromaffin cells (Fig. SI1, in Supporting 
information). These effects are in line with its neuritogenic effects that could be an 
indication of the capacity of IG20 to enhance synaptic plasticity (Garcia-Alvarez et al., 
2015).  
From a strict pharmacological point of view, it can be argued that the capacity of 
IG20 to preserve a better cell viability when hippocampal slices were incubated with the 
three stressors lacked a clear concentration-dependence. For instance, in the case of 
veratridine that elicited quite consistent neuronal damage, IG20 exhibited similar 
protection at the three concentrations used (0.3, 1 and 10 µM) (Fig. 2A). More 
unreliable where the results with glutamate where IG20 afforded significant protection 
at 0.3 and 3 µM but, surprisingly, at 1 and 10 µM there was no protection (Fig. 2A). 
Lastly, the protection afforded by IG20 against OGD neurotoxicity was observed at 1, 3 
and 10 µM; however, in this case the neuroprotective profile of IG20 described a U-
shaped concentration-dependence, a finding suggesting different activities at higher 
concentrations. 
In previous studies we have found that the concentration-dependence of the 
neuroprotective effects of various compounds varies according to the cell/tissue model 
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and the biological targets for those agents. Thus, concentration-dependence was present 
when the targets were ion channels or transporters. This was the case for the nicotinic 
receptor agonist epibatidine in bovine chromaffin cells stressed with 
rotenone/oligomycin (Egea et al., 2007a), with the NMDA receptor blocker minocycline 
in rat hippocampal neurons stressed with glutamate (Gonzalez et al., 2007), or with 
CGP37157, a blocker of the mitochondrial Na
+
/Ca
2+
 exchanger that also target various 
ion channels, in bovine chromaffin cells stressed with veratridine but not with 
rotenone/oligomycin (Nicolau et al., 2009) or in rat hippocampal slices stressed with 
veratridine (Nicolau et al., 2010). However, when the neuroprotective target is a given 
signalling pathway, the concentration-dependence of the compounds is poor or non-
existent. This was the case for the neuroprotective effects of the PPAR receptor agonist 
NP00111 and rosiglitazone, in rat hippocampal slices stressed with OGD (Rosa et al., 
2008), the melatonin-sulforaphane hybrid ITH12674 in rat cortical neurons stressed 
with rotenone/oligomycin or with terbutyl hydroperoxide (Egea et al., 2015), or the 
multitarget ligand ITH33/IQM-21 in rat hippocampal slices stressed with OGD (Lorrio 
et al., 2013). Sulfoglycolipid IG20 seems to belong to this last group of compounds that 
exert neuroprotection through a mechanism that involves a given cellular signalling 
pathway. In line with this proposal are the various families of glycolipids and 
sulfoglycolipids synthesised at our laboratory that by acting on intracellular signalling 
pathways exhibit antimitotic activity in melanoma and glioma cells (Doncel-Perez et al., 
2013; Garcia-Alvarez et al., 2007). In this line is IG20 that belongs to a new family of 
sulfoglycolipids that emerged in the context of the synthesis of new antineoplasic agents 
with potential therapeutic application in glioma and melanoma, and that promoted 
neuritic growth and myelination (Garcia-Alvarez et al., 2015). The question now arises 
on how these plastic effects of IG20 are linked to its neuroprotective effects in 
hippocampal slices here reported.  
IG20 did not affect the [Ca
2+
]c elevations triggered by glutamate in cortical 
neurons (Fig. SI3, Supporting information) and thus a direct action on NMDA/AMPA 
receptors can be discarded. An antioxidant effect of IG20 could explain its 
neuroprotective effects on the basis of two observations namely, its ability to mitigate 
the enhanced ROS production in hippocampal slices stressed with glutamate (Fig. 3C 
and B) or OGD/reox (Fig. 3D) and its capacity to induce the expression of HO-1 (Fig. 
4A) and GCLcat (Fig. 4B). Mitigation of ROS production by some agents have been 
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taken as the basic changes that activate neuroprotective pathways in, for instance, 
chromaffin cells (Egea et al., 2007a) or in cortical neurons stressed with 
rotenone/oligomycin (Egea et al., 2015). Furthermore, blockade of ROS production by 
compound IG20 might induce a stabilization of GSH levels (Fig. 3E) avoiding its 
consumption by radical species. Thus, the reduction of radical species and the 
augmentation of GSH levels can improve mitochondrial function facilitating the 
stabilisation of the membrane potential, favouring the maintenance of ATP levels (Fig. 
3F) and cellular metabolism.  
As mentioned before, compound IG20 is able to increase the expression of HO-1 
and GCLcat in rat primary neuronal cultures after 24 incubation. The ability to induce 
the Nrf2/ARE pathway of compound IG20 might be also related with the activation of 
phase II antioxidant response that induces the expression of antioxidant and anti-
inflammatory enzymes on the other hand, the previously described activity of IG20 over 
glial cells (García-Alvarez et al., 2015) might be responsible for the reduction of iNOS 
expression upon OGD/reox treatment (Fig. 4D).  
The Nrf2/ARE pathway might be activated by different mechanisms such as 
electrophilic modification of Keap1 cysteine residues, by the phosphorylation of 
different kinases related with neuroprotective pathways or by receptor activation 
(Buendia et al., 2015b; Chen et al., 2010). IG20 increased ERK1/2 and Akt 
phosphorylation (Fig. 5B and C). Akt is known to phosphorylate GSK3 at Ser-9 
(Cuchillo-Ibanez et al., 2013; Stambolic and Woodgett, 1994) to inactivate it, promoting 
Nrf2 stabilization and activation of the phase II response (Salazar et al., 2006). Thus, the 
connection between Akt phosphorylation, Nrf2 induction and the reduction of iNOS 
expression is the most plausible neuroprotective pathway that explains the 
neuroprotective effects of IG20.  
An interesting finding was the reduction by IG20 of the sPSCs frequency and 
amplitude (Fig. 6) and the reduction of sAPs frequency (Fig. 7), meaning that neuronal 
excitability is decreased in the presence of the compound. In a previous study performed 
in primary cultures of hippocampal neurons, we found that the neuroprotective effects 
of minocycline could be associated to the mitigation of neuronal excitability, to partial 
blockade of inward Na
+ 
and Ca
2+
 currents, and to decrease Ca
2+
 overloading (Gonzalez 
et al., 2007). Thus, the IG20 neuroprotective effects could in part be explained through 
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mitigation of neuronal excitability, as the case is for minocycline. However, unlike 
minocycline, IG20 did not affect the glutamate elicited [Ca
2+
]c elevations (Fig. SI3, 
Supporting information). In bovine chromaffin cells we found that IG20 augmented INa 
and the large conductance Ca
2+ 
dependent outward K
+ 
currents (BK channels) and the 
exocytotic release of catecholamine without ICa alteration (Crespo-Castrillo et al., 2015). 
Nevertheless, this pharmacological profile in bovine chromaffin cells may not explain 
the neuroprotective effects of IG20 here described.  
Sulfoglycolipid IG20 contains a polar sugar moiety carrying a negatively 
charged OSO3
-1 
group. This could explain our previous finding that the fluorescent 
derivative IG20-NBD remains confined to the plasmalemma of chromaffin cells and 
does not enter into the cell cytosol (Crespo-Castrillo et al., 2015). This suggests that the 
neuroprotection exerted by IG20 may be linked to a membrane-delimited effect. Ig20 
has a molecular structure that reminds the endogenous sulfatide (Fig. 1). Glycolipids are 
predominantly located in the outer plasmalemma layer. Their sulfation introduces 
negative charges that are determinants for interactions with proteic receptors and ion 
channels that might explain the induction of phosphorylation of ERK1/2 and Akt. Thus, 
the neuroprotective effects of IG20 could find an explanation in the context of caveola, 
that are lipid raft domains (Simons and Ikonen, 1997). Raft-enriched lipids such as 
cholesterol and sphingolipids can interact with membrane proteins to regulate the 
activities of ion channels (Dart, 2010). Also, ceramide and sphingosine regulate 
membrane fusion (exocytosis) and fission endocytosis processes (Darios et al., 2009; 
Rosa et al., 2010). Glycolipids are known to be located at the outer plasmalemma layer 
and their sulfation introduces negative charges that are determinants for their 
interactions with proteic receptors and ion channels. They contribute to the regulation of 
cell differentiation, development, cell adhesion, or immune responses (Honke, 2013). 
Additionally, the sulfoglycolipid sulfatide plays a critical role in the regulation of 
oligodendrocytes differentiation and the maintenance of myelin and axonal structure 
(Marcus et al., 2006). Furthermore, altered sphingolipid metabolism has been found in 
some sphingolipidoses, atherosclerosis, diabetes, and cancer (Delgado et al., 2007), as 
well as in early Alzheimer’s disease (Han et al., 2002). Hence, our synthetic compound 
IG20 rises the possibility of regulating some of those physiological and pathological 
processes by using exogenous sulfoglycolipids that promote neuritic growth and 
myelination, inhibit astroglia and microglia proliferation (Garcia-Alvarez et al., 2015), 
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and favour the exocytotic release of neurotransmitters (Crespo-Castrillo et al., 2015). To 
this interesting pharmacological profile, we can now add the IG20 neuroprotective 
effects. 
In conclusion, the novel synthetic sulfoglycolipid IG20 exhibits neuroprotective 
properties in rat hippocampal slices challenged with various stressors. Such effect is 
likely due to its ability to activate the phase II antioxidant response. 
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FIGURE LEGENDS 
Figure 1. Molecular structures of endogenous sulfatide and compound IG20 (oleoyl 2-
N-acetyl-2-amino-2-deoxy-6-O-(oxosulfonyl)-alpha-D-glucopyranoside). 
 
Figure 2: Neuroprotection elicited by IG20 against neurotoxicity elicited by veratridine 
(VTD), glutamate (Glu) and oxygen plus glucose deprivation followed by 
reoxygenation (OGD/reox) in rat hippocampal slices. (A) Experimental 
protocol consists of 30-min preincubation period with IG20 at different 
concentrations, and one hour co-incubation with IG20 and VTD.. (B) 
Neuroprotection elicited by different concentrations of IG20, expressed in 
the ordinate as cell viability. Experimental protocol consists in 2 h 
incubation with glutamate (4 mM) followed by 2 h incubation with different 
concentrations of IG20 in the absence of glutamate. (C) Neuroprotection 
elicited by IG20 against toxicity induced by OGD/reox. The experimental 
protocol consists in 30-min preincubation period with IG20 at different 
concentrations, 15-min under OGD in the presence of IG20 and 2 h of 
reoxygenation with IG20 at the same concentrations. MTT reduction 
measurement, as an indicator of cell viability, is expressed in the ordinates 
as percentage of control. Data are means ± SEM of 6 triplicate experiments. 
###p<0.001 with respect to basal, *p<0.05 and **p<0.01, ***p<0.01 with 
respect to the elicited neuronal damage by each toxic insult. 
 
Figure 3: IG20 drastically reduces the production of reactive oxygen species (ROS) in 
hippocampal slices subjected to glutamate or OGD/reox-induced cellular 
damage and prevents depletion of GSH and ATP induced by OGD/reox. (A 
and B) Representative microphotographs (100X) under each experimental 
condition in the CA1 hippocampal region. (C) Quantification of the ROS 
production in CA1 after 2 h incubation with glutamate (4 mM) followed by 
2 h IG20 incubation at the concentration of 3 M. (D) Mean ROS 
production in CA1 after 15 min OGD followed by 2 h reox with IG20 
incubation at the concentration of 3 M. Data were normalised by nuclei 
staining with Hoechst dye. (E) GSH levels and (F) ATP levels measured 
after OGD/reox in presence or absence of 3 M IG20. Values correspond to 
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means ± SEM of 3 or 4 triplicate experiments performed in hippocampal 
slices from different animals. ##p<0.01 ###p<0.001 with respect to basal; 
*p<0.05, **p<0.01, ***p<0.001 with respect to the corresponding toxic 
alone. 
 
Figure 4: IG20 induces Nrf2/ARE pathway activation in primary neuronal cultures and 
hippocampal slices and reduces iNOS expression after OGD/reox toxic 
insult. (A) HO-1 induction induced by compound IG20 in hippocampal 
neuronal cultures. Neurons were treated with IG20 (3 M) during 24 h. 
Thereafter, cells were collected and HO-1 expression was evaluated by 
western blot analysis. (B) GCLcat induction elicited by exposure of 
neuronal cultures to 3 M IG20.  (C) iNOS expression induced by 
OGD/reox and reduction induced by compound IG20. At the end of the 
experiment slices were collected and protein expression was analysed by 
western blot. Values correspond to means ± SEM of 5 triplicate experiments 
performed in three different cultures (panels A and B) and 4 experiments in 
slices subjected to OGD/reox (panel C). #p<0.05, ##p<0.01 with respect to 
basal conditions; *p<0.05 with respect to OGD/reox alone. 
 
Figure 5: Jak2/Stat3, PI3K/Akt and ERK1/2 survival pathways are involved in the 
neuroprotective effects of IG20 against OGD/reox neurotoxicity. (A) The 
neuroprotective effect of IG20 was partially reverted by 10 M of the 
inhibitors of the signalling pathways Jak2/STAT3 (AG490, AG), ERK1/2 
(PD98059, PD), and PI3K/Akt (LY294002; LY). The experimental protocol 
is depicted in the top part of the panel. Data are expressed as mean ± SEM 
of 7 different experiments. ###p<0.001 with respect to basal; *p<0.05, 
**p<0.01, ***p<0.001 with respect to OGD/reox alone. (B) ERK1/2 
phosphorylation induced by IG20 (3 M) in primary rat neuronal cultures 
after 15, 30 and 60 min incubation measured by western blot. (C) Akt 
phosphorylation induced by IG20 (3 M) in primary rat neuronal cultures 
after 15, 30 and 60 min incubation measured by western blot. Data are 
expressed as means ± SEM of 6 different experiments in triplicate; *p<0.05, 
**p<0.01, *** p<0.001 with respect to basal. 
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Figure 6: Effects of compounds IG20 on spontaneous postsynaptic currents (sPSCs) in 
voltage-clamped hippocampal neurons. (A) Representative traces of an 
original record in the voltage-clamp configuration of the patch-clamp 
technique, with the holding potential fixed at -80 mV. Plot of normalised 
frequency (B), amplitude (C), and area (D) of sPSCs, calculated at 10-s 
periods with respect to control. Experimental conditions are indicated by the 
horizontal bars at the bottoms of panels B, C, and D. Data are means±SEM 
of the number of cells and cultures shown in parentheses. *p<0.05, 
**p<0.01, and ***p<0.001 with respect to control. 
 
Figure 7: Sulfoglycolipid IG20 reduces the frequency of spontaneous action potentials 
(sAPs) in current-clamped hippocampal neurons. (A) Records from an 
example neuron, and the effects of IG20 applied at the indicated 
concentrations and time periods indicated by the bottom horizontal bars. (B) 
Normalised frequency of sAPs under control conditions, and in the presence 
of 1 or 10 M IG20. Data are means ± SEM of the number of cells shown in 
parentheses. **p<0.01, and ***p<0.001 with respect to control. 
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